Prophylactic use of an inducer invokes the necessity of repeated doses of the inducer. The double-stranded ribonucleic acid (DS-RNA)-containing mycophage particles (2, 9, 10), the predominant factor in statolon responsible for activity, are antigenic. A second dose of statolon could then be precluded from inducing interferon due to neutralization by antibody. The response to repeated doses of statolon has, therefore, been studied.
(IN) route, a common portal of entry for many viruses. The fact that viruses are airborne even for relatively long distances (7) emphasizes the desirability of protection via this route.
We have found that one prophylactic dose of statolon, an interferon inducer derived from Penicilliwn stoloniferwn, has a protective duration of activity of 30 days against MM virus in mice (11) . Statolon administered prophylactically IN 16 hr before infection has also been found to protect mice against influenza virus inoculated via the same route (8) . Because Prophylactic use of an inducer invokes the necessity of repeated doses of the inducer. The double-stranded ribonucleic acid (DS-RNA)-containing mycophage particles (2, 9, 10) , the predominant factor in statolon responsible for activity, are antigenic. A second dose of statolon could then be precluded from inducing interferon due to neutralization by antibody. The response to repeated doses of statolon has, therefore, been studied.
MATERIALS AND METHODS Statolon. Statolon preparations similar to those previously described were employed (8, 11, 12 Interferon assays. Interferon titers were determined by the mouse L cell-vesicular stomatitis virus (VSV) system. Titers were read from the decrease in plaques relative to nontreated control cells; a unit of interferon is the reciprocal of the dilution producing a 50% decrease in plaque count.
Determination of interferon in the tracheae and lungs. Fifteen mice, 11 to 13 g, were treated IN with 0.05 ml (300 Mg) of statolon. The same number of control mice were treated IN with saline. After 16 hr the mice were sacrificed, and the lungs and tracheae were separately excised. The tracheae were homogenized in 3 ml of tissue culture medium 199, the lungs in 7.5 ml of M199. The homogenates were centrifuged at 105,000 X g for 30 min. The supernatant fluids were adjusted to pH 4.5 and centrifuged again at 105,000 X g for 90 min to remove any residual statolon that might be present. The fluids were then assayed for interferon.
RESULTS
Dose response. Previous studies with statolon instilled IN showed it to be effective against in- Table 2 show a definite duration of activity, lasting I to 2 weeks. In these experiments, a prolonged survival of 1 to 3 days over that of the nontreated animals was observed consistently among the animals that were treated but did not survive, a further reflection of the activity of the inducer.
Effectiveness of repeated doses. Because antibodies to the statolon particle (mycophage) might prevent restimulation of interferon production on repeated application of statolon, the effect of a second dose, 2 weeks after the initial dosing, a period sufficiently long to allow production of antibody, was determined. The results in Table 3 demonstrate that a second dose of statolon indeed is effective in reducing infection. Variability in survival in these experiments is obvious (Tables  2 and 3) , particularly in line 3 of Table 3 , where no survivors are indicated at 14 days after one treatment with statolon. Such variability is attributed to the method of administration, accomplished by applying a drop of solution on the nose of the mouse, a method that does not always deliver a consistent quantitative dose.
)An experiment was also conducted to ascertain whether doses of statolon repeated weekly would influence the effectiveness ofthe inducer. In Table  4 , we see that four doses of statolon administered one week apart showed even a higher response of Our previous studies (8) showed that, although interferon is found in the lungs of mice injected intraperitoneally with statolon, protection is not afforded against IN infection with influenza. Interferon was also found in lungs of protected animals treated IN with statolon but not in their sera. The situation is similar to the characteristics of localization observed with immunoglobulin A(IgA) formed on IN instillation of viral vaccines (13, 14, 18) . We concluded that interferon is synthesized at distal sites and, though found in the lung, does not reach the cells of the mucous surface of the respiratory tract and therefore cannot contribute to defense against viral invasion. The results of other investigators also provide evidence that a barrier prevents accessibility of circulating interferon to the surface cells of the respiratory tract (1, 4, 15) . Direct treatment of potential target cells of the respiratory tract with statolon, however, results in the production of interferon in the cells with concomitant protection. The fact that interferon is found in the tracheae as well as the lungs of treated mice substantiates our previous observation and indicates that interferon is present in the cells throughout the tract after treatment with the inducer.
Although the protection observed in these experiments is not always total, i.e., 100% of animals protected, nevertheless, the protection is indeed highly significant especially when one considers the high infective dose of 10 LD50 units of virus employed. Such a severe challenge would probably not be met under conditions of natural transmission, and prophylactic protection against a few airborne particles impinging on the nasal tract would easily be obtained.
These experiments in mice are designed as a model system for eventual application against human infections. The duration of activity of a prophylactically administered antiviral agent would be of great importance clinically. The persistence of the protective effect of intranasally instilled statolon in mice is sufficiently prolonged to make statolon a candidate for similar testing to determine its efficacy via the extranasal route in man. Hyporeactivity seen with statolon lasting about five days (11) , during which time further interferon formation is switched off, would not pose a problem, for the duration of activity exceeds this period. Hill et al. (5) have observed protection in mice against influenza virus with IN administered poly inosinic acid :poly cytidylic acid (poly I:C), the synthetic DS-RNA molecule, a potent inducer of interferon (3). DS-RNA from several sources instilled IN has been reported by Hilleman (6) to exert activity against pneumonia virus of mice, and DS-RNA from the mycophage particle of P. stoloniferum administered IN was found by Planterose et al. (16) to protect mice against influenza. The duration of activity of such free DS-RNA, however, may not be as long as that seen with the intact virus or mycophage (16). Schmidt et al. (17) have recently studied the duration of resistance to MM virus infection of several interferon inducers inoculated intraperitoneally and found statolon to possess a significantly greater duration of activity than poly I:C. Comparative animal studies of the duration of inhibitory activity of the intact DS-RNA-containing particle versus its free DS-RNA via the nasal route are needed, but longer duration of the intact particle would be expected because of slower release of the DS-RNA and protection against nuclease action.
Although statolon is antigenic, its virus inhibitory activity was not neutralized on repeated use in the experiments on mice reported here.
Hence there is no theoretical reason to assume that this difficulty would preclude its repeated intranasal administration in clinical trials. As many as four intranasal applications one week apart did not interfere with activity of this inducer. The antigenicity of the statolon particle may inherently be exceedingly low. Also, IgA, the secretory antibody formed in the respiratory tract, is known to possess a short half-life, and anemnesis apparently does not occur (13) . The antibody is very likely sloughed off regularly from the mucous surface in time to permit the response of a repeated dose of inducer.
Blocking the development of viral infection at the site of entry of the virus by prophylactic administration of interferon inducers presents great potentialities for eventual clinical use of such inducers. Intranasal administration is particularly attractive. Not only is the intranasal route the most effective route for administration of interferon inducers against respiratory infection, but it also obviously is a route of least hazard, inconvenience, and discomfort. The demonstration of duration of activity, low antigenicity, and efficacy via the convenient intranasal route with statolon reported here in studies in mice may offer promise to a successful approach in humans to viral control in the respiratory tract.
